SAMD00766047
External Id
RIKEN-IFOM Joint Laboratory for Cancer Genomics Center for Integrative Medical Sciences, RIKEN
INSDC center name
2024-04-30T00:00:00Z
INSDC first public
2024-05-12T18:13:01.733Z
INSDC last update
DRS377740
INSDC secondary accession
live
INSDC status
Human
NCBI submission model
Human.1.0
NCBI submission package
DRS377740
SRA accession
not applicable
age
RIKEN BRC
biomaterial_provider
Jurkat
cell_line
acute T cell leukemia
cell_subtype
acute T cell leukemia
cell_type
2023-08-11
collection_date
Jurkat cells (a human T lymphocyte cell line, RCB0806) were obtained from the RIKEN BRC. dCas9-VP64_GFP (plasmid 61422; Addgene) and Lenti_MS2_P65_HSF1_2A_puro (plasmid 118699; Addgene) were gifts from F. Zhang and C. Vakoc, respectively. CRISPRa- Jurkat cell line stably expressing dCas9-VP64 and MS2_P65_HSF1 was established by lentiviral transduction and subsequent selection of GFP-expressing puromycin-resistant cells. Protospacer adjacent motif (PAM) sequence for each bidirectionally transcribed candidate enhancer (btcEnh) region was designed using Custom Alt-RTM CRISPR-Cas9 guide RNA design tool. A 130-base single-guide RNA (sgRNA) harboring an MS2 stem-loop sequence was synthesized by IDT with 2??-O-methyl-modified phosphorothioate modifications at three bases at each 5?? and 3?? end. Non-targeting control sgRNA or targeting sgRNA (100 nM) was transfected to CRISPRa-Jurkat cells using DharmaFECT 4 (Horizon Discovery).
description
acute T cell leukemia
disease
Caucasian
ethnicity
Japan
geo_loc_name
Tumor
health_state
not applicable
isolate
Homo sapiens
http://purl.obolibrary.org/obo/NCBITaxon_9606
organism
Tumor
phenotype
Caucasian
population
Caucasian
race
Jurkat_CRISPRa_chr1_2585282_2586074-CAGE
sample_name
male
sex
Blood
tissue
Jurkat cells with CRISPR activation of selected disease-relevant bidirectionally transcribed candidate enhancers (chr1:2585282-2586074) for CAGE
title
Jurkat cells (a human T lymphocyte cell line, RCB0806) were obtained from the RIKEN BRC. dCas9-VP64_GFP (plasmid 61422; Addgene) and Lenti_MS2_P65_HSF1_2A_puro (plasmid 118699; Addgene) were gifts from F. Zhang and C. Vakoc, respectively. CRISPRa- Jurkat cell line stably expressing dCas9-VP64 and MS2_P65_HSF1 was established by lentiviral transduction and subsequent selection of GFP-expressing puromycin-resistant cells. Protospacer adjacent motif (PAM) sequence for each bidirectionally transcribed candidate enhancer (btcEnh) region was designed using Custom Alt-RTM CRISPR-Cas9 guide RNA design tool.
treatment